373 related articles for article (PubMed ID: 9464821)
1. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K
Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637
[TBL] [Abstract][Full Text] [Related]
5. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
7. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
Thabard W; Barillé S; Collette M; Harousseau JL; Rapp MJ; Bataille R; Amiot M
Clin Cancer Res; 1999 Oct; 5(10):2693-7. PubMed ID: 10537331
[TBL] [Abstract][Full Text] [Related]
8. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
[TBL] [Abstract][Full Text] [Related]
9. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y
Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes.
Gabay C; Silacci P; Genin B; Mentha G; Le Coultre C; Guerne PA
Eur J Immunol; 1995 Aug; 25(8):2378-83. PubMed ID: 7545121
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes.
Paysant J; Blanqué R; Vasse M; Soria C; Soria J; Gardner CR
Cytokine; 2000 Jun; 12(6):774-9. PubMed ID: 10843763
[TBL] [Abstract][Full Text] [Related]
13. Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor.
Karadag A; Scutt AM; Croucher PI
J Bone Miner Res; 2000 Oct; 15(10):1935-43. PubMed ID: 11028445
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
15. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
16. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
17. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.
Jiang XP; Yang DC; Elliott RL; Head JF
Anticancer Res; 2011 Sep; 31(9):2899-906. PubMed ID: 21868536
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
20. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
